3B Blackbio DX Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹25Cr
- +38.9% YoY
- −13.8% QoQ
- Net profit
- ₹13Cr
- +44.4% YoY
- −13.3% QoQ
- Margin
- 59%
- +9 pp YoY
- +4 pp QoQ
Guidance rank: #34 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
Based on 3B Blackbio DX Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Consolidated Revenue from Operations Q3 FY 2024-25: ₹2,539.25 Lakh vs ₹1,766.89 Lakh in Q3 FY 2023-24 (↑ approx. 44%). EBITDA Q3 FY 2024-25: Rs. 1,783.89 Lakh.
From 3B Blackbio DX Ltd's Q3 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Consolidated Revenue from Operations Q3 FY 2024-25: ₹2,539.25 Lakh vs ₹1,766.89 Lakh in Q3 FY 2023-24 (↑ approx. 44%)
- Profit Before Tax Q3 FY 2024-25: ₹1,779.62 Lakh vs ₹1,115.19 Lakh (↑ approx. 60%)
- Profit After Tax Q3 FY 2024-25: ₹1,349.53 Lakh vs ₹851.68 Lakh (↑ approx. 58%)
- Diagnostics Division Revenue Q3 FY 2024-25: ₹2,328.30 Lakh (including TRUPCR Europe sales) vs ₹1,531.37 Lakh (↑ approx. 52%)
- Export Sales Q3 FY 2024-25: ₹587.24 Lakh vs ₹267.20 Lakh (↑ approx. 120%)
- TRUPCR Europe Q3 FY 2024-25 sales: GBP 417,623 vs GBP 133,508 (↑ approx. 213%)
- Business Outlook:
- Molecular Diagnostics to grow 20-25% annually
- Export/international business targeted growth of 20-25%
2 more points from 3B Blackbio DX Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is continuously investing in additional manufacturing and R&D facilities/capacities to cater to existing business verticals.
- Focus on designing and launching new products to meet increasing market needs, especially in syndromic testing panels, maintaining first-mover advantage (Page 35).
- Deployment of some funds planned in a joint venture in Manchester, UK, depending on need (Page 35).
2 more points from 3B Blackbio DX Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
3B Blackbio DX Ltd — Quarterly revenue & net profit
3B Blackbio DX Ltd Q3 FY25 results — key figures
| ₹ Cr | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 25 | 18 | +38.9% | 29 | -13.8% |
| Operating profit (EBITDA) | 15 | 9 | +66.7% | 16 | -6.2% |
| Operating margin | 59% | 50% | +9 pp | 55% | +4 pp |
| Profit before tax | 18 | 11 | +63.6% | 19 | -5.3% |
| Net profit (PAT) | 13 | 9 | +44.4% | 15 | -13.3% |
| EPS (₹) | 15.61 | 10.16 | +53.6% | 17.07 | -8.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What 3B Blackbio's management said in earlier quarters
Others in Healthcare Services this season
- Vimta Labs (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
- Rainbow Childrens Medicare (Q3 FY25)
Mature hospitals show approximately 9% inpatient (IP) volume growth on a like-to-like basis. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
- Dr Lal Pathlabs (Q3 FY25)
Swasthfit (bundle test program) continues strong growth (27.2% in Q3 FY25), with plans to expand market penetration beyond Tier-1 and Tier-2 cities. Key…
- Thyrocare Technologies (Q3 FY25)
Franchise revenue grew 24% YoY, partnerships business grew 23% YoY, and radiology business increased 13% YoY. Key concall takeaways from Thyrocare Technologies…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
3B Blackbio DX Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were 3B Blackbio DX Ltd Q3 FY25 results?
Consolidated Revenue from Operations Q3 FY 2024-25: ₹2,539.25 Lakh vs ₹1,766.89 Lakh in Q3 FY 2023-24 (↑ approx. 44%). EBITDA Q3 FY 2024-25: Rs. 1,783.89 Lakh.
What is 3B Blackbio DX Ltd share price analysis?
3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹1,132 Cr. Investors should review the full earnings analysis for detailed insights.
Is 3B Blackbio DX Ltd planning capital expenditure?
The company is continuously investing in additional manufacturing and R&D facilities/capacities to cater to existing business verticals.
Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
